Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant darovasertib for localized large uveal melanoma before enucleation or plaque brachytherapy
ISRCTN12292888Phase 2Active, not recruiting
- Sponsor
- United BioSource
- Start
- Aug 2023
- Modality
- Small Molecules
01
Overview
Phase 2, open-label trial of darovasertib in intraocular melanoma (2 cohorts), sponsored by United BioSource. Primary endpoints: Adverse events leading to dose changes, Severe adverse events and laboratory abnormalities and 3 more. Started Aug 2023; status: active, not recruiting.
02
Drugs
darovasertib
03
Conditions
intraocular melanoma
Beyond the preview
Go deeper on ISRCTN12292888.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN12292888.